04:38 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

ARID5A as a therapy for obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Raising activity levels of the transcription factor ARID5A could help treat obesity by inhibiting PPARγ-mediated adipogenesis. ARID5A overexpression decreased adipogenesis and repressed transcription of PPARγ, a master regulator of the...
17:53 , Jun 11, 2019 |  BC Extra  |  Clinical News

CymaBay down on Phase IIb NASH miss

CymaBay fell $5.04 (45%) to $6.05 on Tuesday after the company announced seladelpar missed the primary endpoint in a Phase IIb trial to treat NASH. In 181 patients with biopsy-confirmed NASH, CymaBay Therapeutics Inc. (NASDAQ:CBAY)...
21:28 , May 24, 2019 |  BC Extra  |  Company News

May 24 Company Quick Takes: End of Alpine-Kite deal; plus Jakafi label expansion and more

Kite ends immunotherapy deal with Alpine  Alpine Immune Sciences Inc. (NASDAQ:ALPN) said Kite Pharma Inc. terminated a 2015 deal to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. The deal granted...
12:00 , May 20, 2019 |  BioCentury  |  Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
00:07 , May 10, 2019 |  BC Innovations  |  Translation in Brief

Tapping mutations for liver regeneration

Certain mutations in patients with chronic liver disease may be helpful rather than harmful, and could be tapped for regenerative medicine, according to a team from the Children’s Medical Center Research Institute at UT Southwestern....
02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
12:19 , Apr 4, 2019 |  BC Extra  |  Financial News

Liver disease play NGM raises $106.7M in IPO

Shares in NGM slipped $1.30 to $14.70 on Thursday after the company raised $106.7 million in an IPO that priced at the top of the company's proposed range. NGM Biopharmaceuticals Inc. (NASDAQ:NGM) sold 6.7 million...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
13:47 , Mar 27, 2019 |  BC Extra  |  Financial News

NASH company Genfit gains dual listing via NASDAQ offering

Liver disease company Genfit gained $1.85 to $22.17 on Wednesday after the company raised a combined $135.1 million via a NASDAQ offering and concurrent private placement. In the NASDAQ offering, Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) raised...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...